Raptor Pharma (RPTP) Tops Q2 EPS by 2c; Raises Outlook

Raptor Pharma (NASDAQ: RPTP) reported Q2 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $32 million versus the consensus estimate of $28.52 million.

“I’m delighted that we delivered another record quarter for sales, driven primarily by growing patient demand for PROCYSBI ,” said Julie Anne Smith, President and CEO of Raptor. “For the first time, PROCYSBI revenue was augmented by sales of QUINSAIR, which is off to a terrific launch in Europe. Based on our outstanding commercial performance, we are pleased to raise our 2016 revenue guidance. We look forward to continued growth from both products and supporting patients living with rare diseases and with limited options.”

GUIDANCE:

Raptor Pharma sees FY2016 revenue of $125-135 million, versus prior guidance of $115-125 million and the consensus of $117.41 million.

For earnings history and earnings-related data on Raptor Pharma (RPTP) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance